Literature DB >> 22344686

MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways.

B Nelson Chau1, Cuiyan Xin, Jochen Hartner, Shuyu Ren, Ana P Castano, Geoffrey Linn, Jian Li, Phong T Tran, Vivek Kaimal, Xinqiang Huang, Aaron N Chang, Shenyang Li, Aarti Kalra, Monica Grafals, Didier Portilla, Deidre A MacKenna, Stuart H Orkin, Jeremy S Duffield.   

Abstract

Scarring of the kidney is a major public health concern, directly promoting loss of kidney function. To understand the role of microRNA (miRNA) in the progression of kidney scarring in response to injury, we investigated changes in miRNA expression in two kidney fibrosis models and identified 24 commonly up-regulated miRNAs. Among them, miR-21 was highly elevated in both animal models and in human transplanted kidneys with nephropathy. Deletion of miR-21 in mice resulted in no overt abnormality. However, miR-21(-/-) mice suffered far less interstitial fibrosis in response to kidney injury, a phenotype duplicated in wild-type mice treated with anti-miR-21 oligonucleotides. Global derepression of miR-21 target mRNAs was readily detectable in miR-21(-/-) kidneys after injury. Analysis of gene expression profiles up-regulated in the absence of miR-21 identified groups of genes involved in metabolic pathways, including the lipid metabolism pathway regulated by peroxisome proliferator-activated receptor-α (Pparα), a direct miR-21 target. Overexpression of Pparα prevented ureteral obstruction-induced injury and fibrosis. Pparα deficiency abrogated the antifibrotic effect of anti-miR-21 oligonucleotides. miR-21 also regulated the redox metabolic pathway. The mitochondrial inhibitor of reactive oxygen species generation Mpv17l was repressed by miR-21, correlating closely with enhanced oxidative kidney damage. These studies demonstrate that miR-21 contributes to fibrogenesis and epithelial injury in the kidney in two mouse models and is a candidate target for antifibrotic therapies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22344686      PMCID: PMC3672221          DOI: 10.1126/scitranslmed.3003205

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  57 in total

1.  Human Mpv17-like protein is localized in peroxisomes and regulates expression of antioxidant enzymes.

Authors:  Reiko Iida; Toshihiro Yasuda; Etsuko Tsubota; Hisakazu Takatsuka; Takasumi Matsuki; Koichiro Kishi
Journal:  Biochem Biophys Res Commun       Date:  2006-04-19       Impact factor: 3.575

Review 2.  Regulation of fibrosis by the immune system.

Authors:  Mark L Lupher; W Michael Gallatin
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

3.  Control of stress-dependent cardiac growth and gene expression by a microRNA.

Authors:  Eva van Rooij; Lillian B Sutherland; Xiaoxia Qi; James A Richardson; Joseph Hill; Eric N Olson
Journal:  Science       Date:  2007-03-22       Impact factor: 47.728

Review 4.  Peroxisomes and oxidative stress.

Authors:  Michael Schrader; H Dariush Fahimi
Journal:  Biochim Biophys Acta       Date:  2006-09-14

Review 5.  Progression in chronic kidney disease.

Authors:  Allison A Eddy
Journal:  Adv Chronic Kidney Dis       Date:  2005-10       Impact factor: 3.620

6.  A potential link between muscle peroxisome proliferator- activated receptor-alpha signaling and obesity-related diabetes.

Authors:  Brian N Finck; Carlos Bernal-Mizrachi; Dong Ho Han; Trey Coleman; Nandakumar Sambandam; Lori L LaRiviere; John O Holloszy; Clay F Semenkovich; Daniel P Kelly
Journal:  Cell Metab       Date:  2005-02       Impact factor: 27.287

Review 7.  Recklessness as a hallmark of aggressive cancer.

Authors:  Makoto Noda; Chiaki Takahashi
Journal:  Cancer Sci       Date:  2007-08-28       Impact factor: 6.716

8.  Switching from repression to activation: microRNAs can up-regulate translation.

Authors:  Shobha Vasudevan; Yingchun Tong; Joan A Steitz
Journal:  Science       Date:  2007-11-29       Impact factor: 47.728

9.  Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease.

Authors:  Michael Zeisberg; Mona Khurana; Velidi H Rao; Dominic Cosgrove; Jean-Philippe Rougier; Michelle C Werner; Charles F Shield; Zena Werb; Raghu Kalluri
Journal:  PLoS Med       Date:  2006-03-07       Impact factor: 11.069

10.  MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion.

Authors:  Antonella Spinazzola; Carlo Viscomi; Erika Fernandez-Vizarra; Franco Carrara; Pio D'Adamo; Sarah Calvo; René Massimiliano Marsano; Claudia Donnini; Hans Weiher; Pietro Strisciuglio; Rossella Parini; Emmanuelle Sarzi; Alicia Chan; Salvatore DiMauro; Agnes Rötig; Paolo Gasparini; Iliana Ferrero; Vamsi K Mootha; Valeria Tiranti; Massimo Zeviani
Journal:  Nat Genet       Date:  2006-04-02       Impact factor: 38.330

View more
  235 in total

Review 1.  MicroRNAs in renal development.

Authors:  Jacqueline Ho; Jordan A Kreidberg
Journal:  Pediatr Nephrol       Date:  2012-06-02       Impact factor: 3.714

Review 2.  MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets.

Authors:  Mitsuo Kato; Rama Natarajan
Journal:  Ann N Y Acad Sci       Date:  2015-04-15       Impact factor: 5.691

3.  Hyperactive FOXO1 results in lack of tip stalk identity and deficient microvascular regeneration during kidney injury.

Authors:  Lan T H Dang; Takahide Aburatani; Graham A Marsh; Bryce G Johnson; Stella Alimperti; Christine J Yoon; Angela Huang; Suzanne Szak; Naoki Nakagawa; Ivan Gomez; Shuyu Ren; Sarah K Read; Chris Sparages; Alfred C Aplin; Roberto F Nicosia; Chris Chen; Giovanni Ligresti; Jeremy S Duffield
Journal:  Biomaterials       Date:  2017-07-07       Impact factor: 12.479

Review 4.  Cellular mechanisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis.

Authors:  Gabriela Campanholle; Giovanni Ligresti; Sina A Gharib; Jeremy S Duffield
Journal:  Am J Physiol Cell Physiol       Date:  2013-01-16       Impact factor: 4.249

Review 5.  MicroRNAs in the pathogenesis of cystic kidney disease.

Authors:  Yu Leng Phua; Jacqueline Ho
Journal:  Curr Opin Pediatr       Date:  2015-04       Impact factor: 2.856

Review 6.  Targeting the progression of chronic kidney disease.

Authors:  Marta Ruiz-Ortega; Sandra Rayego-Mateos; Santiago Lamas; Alberto Ortiz; Raul R Rodrigues-Diez
Journal:  Nat Rev Nephrol       Date:  2020-02-14       Impact factor: 28.314

7.  EphrinB2 reverse signaling protects against capillary rarefaction and fibrosis after kidney injury.

Authors:  Yujiro Kida; Nicholas Ieronimakis; Claudia Schrimpf; Morayma Reyes; Jeremy S Duffield
Journal:  J Am Soc Nephrol       Date:  2013-03-14       Impact factor: 10.121

8.  PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice.

Authors:  Ronak Lakhia; Matanel Yheskel; Andrea Flaten; Ezekiel B Quittner-Strom; William L Holland; Vishal Patel
Journal:  Am J Physiol Renal Physiol       Date:  2017-09-13

Review 9.  The proximal tubule is the primary target of injury and progression of kidney disease: role of the glomerulotubular junction.

Authors:  Robert L Chevalier
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-18

10.  Pentraxin-2 suppresses c-Jun/AP-1 signaling to inhibit progressive fibrotic disease.

Authors:  Naoki Nakagawa; Luke Barron; Ivan G Gomez; Bryce G Johnson; Allie M Roach; Sei Kameoka; Richard M Jack; Mark L Lupher; Sina A Gharib; Jeremy S Duffield
Journal:  JCI Insight       Date:  2016-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.